董佳丽,程 贞,李姝君,等.非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展[J].肿瘤学杂志,2024,30(6):510-517.
非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展
Research Progress on EGFR-TKI Targeted Therapy for Non-Small Cell Lung Cancer
投稿时间:2023-09-29  
DOI:10.11735/j.issn.1671-170X.2024.06.B010
中文关键词:  癌,非小细胞肺  表皮生长因子受体-酪氨酸激酶抑制剂  耐药  全程管理  靶向治疗  新辅助治疗  辅助治疗
英文关键词:cancer, non-small cell lung  epidermal growth factor receptor-tyrosine kinase inhibitors  drug resistance mechanism  whole-process management  targeted therapy  neoadjuvant therapy  adjuvant therapy
基金项目:
作者单位
董佳丽 广东医科大学附属医院 
程 贞 广东医科大学附属医院 
李姝君 广东医科大学附属医院 
王永存 广东医科大学附属医院 
摘要点击次数: 178
全文下载次数: 81
中文摘要:
      摘 要:以表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors ,EGFR-TKIs)为代表的靶向治疗药物已显著改善非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的预后。随着肿瘤全程管理的推进,不断有研究展开探讨EGFR-TKIs在新辅助治疗、辅助治疗及晚期一线治疗(EGFR-TKIs单药治疗和联合化疗、抗血管生成治疗及免疫治疗)中的疗效。而EGFR-TKIs耐药成为靶向治疗无法避免的问题,导致耐药后的治疗陷入瓶颈。全文就EGFR-TKIs的临床应用、耐药机制及抗耐药治疗进行综述。
英文摘要:
      Abstract: Targeted therapy represented by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the prognosis of patients with non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs (including EGFR-TKIs monotherapy and combined with chemotherapy, anti-angiogenesis therapy and immunotherapy) in neoadjuvant therapy, adjuvant therapy and first-line treatment for advanced-stage patients has been extensively explored. However, resistance to EGFR-TKIs in targeted therapy has become a challenge leading to the difficulty in post-resistance treatment. This paper reviews the clinical application, resistance mechanisms and anti-resistance treatments of EGFR-TKIs.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器